Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. University General Hospital of Heraklion, Crete, Greece

Survival: 8.8 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Platinol
Country: Greece
City/State/Province: Crete
Hospital: University General Hospital of Heraklion
Journal: Link
Date: 10/2005

Patients: This Phase II study involved 139 patients with advanced non-small-cell lung cancer. All patients were treated previously with taxanes and gemcitabine. The patients were randomized into two groups. Group B had 68 patients (58 men, 10 women) with a median age of 64 years.

Treatment: For Group B, treatment consisted of one chemotherapeutic agent: cisplatin.

Toxicity: For Group B, grade 3-4 toxicities include asthenia, neutropenia, nausea/vomiting, and thrombocytopenia.

Results: For Group A (irinotecan and cisplatin), the median overall survival was 7.8 months. For Group B (cisplatin only), the median overall survival was 8.8 months. The authors concluded, "The irinotecan and cisplatin regimen did not confer a survival benefit compared with cisplatin as second-line treatment of patients with advanced NSCLC pretreated with a taxane/gemcitabine regimen, despite its better efficacy in terms of response rate."

Correspondence: Dr. V. Georgoulias

E-mail to a Friend Email Physician More Information